Creating new treatments for antibiotic-resistant bacteria
Official title: Development of Therapeutic Products for Antibiotic Resistant Bacteria
Funded at Microbiotix, INC · NIH-11140253 · Data updated 2026-11-12
This study is working on creating new treatments to help fight infections caused by tough bacteria that don't respond to regular antibiotics, so patients can have better options for getting better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Microbiotix, INC NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | July 1, 2020 |
| Project end | October 14, 2025 |
| Funding year | 2024 |
| Award (this year) | $2,485,753 |
| NIH project number | 75N93020C00019-P00012-9999-1 |
| Project ID | NIH-11140253 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
✕Less likely to help
Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
What this research studies
This research focuses on developing new therapeutic products to combat antibiotic-resistant bacteria, particularly those that pose a threat to public health. The approach includes optimizing lead compounds, selecting the best candidates for further development, and conducting preclinical studies to ensure safety and efficacy. Patients may benefit from innovative treatments that could effectively target infections caused by resistant strains of bacteria, such as Pseudomonas aeruginosa. The research aims to advance these products through rigorous testing and regulatory processes.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for infections caused by antibiotic-resistant bacteria, improving patient outcomes.
How similar studies have gone: Previous research has shown promise in developing therapies for antibiotic-resistant infections, indicating that this approach has potential for success.
Where this research is happening
-
Microbiotix, INC
Worcester, United States Active
Researchers
- Principal investigator: Bowlin, Terry — Microbiotix, INC
- Study coordinator: Bowlin, Terry
Related research
Other NIH-funded projects on the same topics.
-
Novel Benzyl-Piperidine antifungals to fight hard-to-treat mucormycosis
A new drug candidate series called Benzyl-Piperidines is being developed to treat invasive mucormycosis, a deadly fungal infection often affecting people with weakened immune systems.
-
Well-tolerated new drugs to fight drug-resistant CMV in transplant patients
A new class of CMV drugs that are easier to tolerate is being developed to prevent or treat CMV infections in people who have had solid organ or bone marrow transplants.
-
Discovery of small-molecule inhibitors to stop bunyavirus endonuclease
A small-molecule approach is being developed to block a key enzyme of bunyaviruses like Rift Valley fever, with the goal of preventing or treating infections in people and animals.
-
Filociclovir eye drops for adenoviral conjunctivitis and epidemic keratoconjunctivitis
This project is developing an antiviral eye drop, filociclovir, to treat adenovirus eye infections like conjunctivitis and the more severe epidemic keratoconjunctivitis.
-
Finding new treatments for a dangerous mosquito-borne virus.
This study is working on new antiviral medicines to help fight the Rift Valley Fever Virus, which can make people very sick, by creating tiny molecules that stop the virus from spreading, since there are no approved treatments or vaccines for it yet.
-
Developing new treatments for burn wound infections caused by antibiotic-resistant bacteria.
This study is looking at a new treatment to help fight infections from a tough bacteria called Pseudomonas aeruginosa that can affect burn wounds, and if successful, it could offer better care for patients dealing with these kinds of infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.